Combination chemotherapy with vindesine-ifosfamide-cisplatin (VIP) in locally advanced unresectable stage III and in stage IV non-small cell lung cancer: a phase II trial
| Autor: | F. Verhelst, P. Bertrand, J. Verschuere, S. Marien, L. Roex, Johan Vansteenkiste, A. Verstraete, J. Vandebroek, R. Deman, H. Ulrichts, T. De Beukelaar, Maurits Demedts, J. Bockaert, P. De Muynck, W. Van Kerckhoven |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Adult
Male Pulmonary and Respiratory Medicine Cancer Research medicine.medical_specialty Lung Neoplasms Time Factors Vindesine medicine.medical_treatment Adenocarcinoma Gastroenterology chemistry.chemical_compound Carcinoma Non-Small-Cell Lung Internal medicine Antineoplastic Combined Chemotherapy Protocols Weight Loss Confidence Intervals medicine Humans Ifosfamide Prospective Studies Survival rate Aged Neoplasm Staging Chemotherapy Chi-Square Distribution business.industry Induction chemotherapy Combination chemotherapy Middle Aged Nitrogen mustard Surgery Survival Rate Regimen Oncology chemistry Carcinoma Squamous Cell Carcinoma Large Cell Female Cisplatin business medicine.drug |
| Zdroj: | Lung Cancer. 13:295-303 |
| ISSN: | 0169-5002 |
| Popis: | The efficacy and toxicity of a regimen adding ifosfamide to the more classical cisplatin-vindesine combination was studied in patients with advanced non-small cell lung cancer. Sixty-four good performance patients with inoperable stage III or stage IV were treated with VIP: vindesine 3 mg/m 2 days 1 and 8, ifosfamide 1200 mg/m 2 and platinum 30 mg/m 2 days 1, 2 and 3, repeated every 4 weeks, up to a maximum of six cycles. Response rate, clinical data and radiological tests were rigourously reviewed by a panel. Overall response rate was 39% (95% confidence interval, 27%–51%) with three patients achieving a complete response; response rate in stage III was 48%. Median survival was 9 months. Toxicity consisted mainly of bone marrow toxicity and nausea/vomiting, but was manageable. There was no renal toxicity greater than grade 2, four severe infections, but no treatment-related deaths. Conclusion: VIP as mentioned above is very active in good performance patients with advanced non-small cell lung cancer. Its activity, together with its manageable toxicity—without severe renal or pulmonary toxicity—makes it an attractive candidate for induction chemotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect